Evelo Biosciences, Inc. (NASDAQ:EVLO)
Industry: PharmaceuticalsMajor

OFF LIST - 2868 consecutive market days: OFF LIST as of 01/13/2005 Through 11/14/2016

Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Current Quote*
Last: $5.249
Change: -0.021
Book: $3.143
Volume: 18,040

As Of: 02/25 12:46 ET
*Quotes delayed by 20min.

Graphs for EVLO


3 Month Graph


6 Month Graph


1 Year Graph